Bonerge Initiates Clinical Trial on Urolithin A and Fisetin for Sleep & Wellbeing

NEW YORK–(BUSINESS WIRE)–In 2025, Bonerge initiated a clinical trial (Registration #NCT06990256) investigating the effects of Urolithin A and Fisetin on sleep quality, targeting sleep disorders through the lens of ageing biology.

This randomized, quadruple-blind (participants, healthcare providers, researchers, assessors), placebo-controlled study will enroll over 80 participants aged 45-70. They will be divided into four groups: Urolithin A alone, Fisetin alone, Urolithin A + Fisetin combination, and placebo control. The 12-week intervention represents the first systematic evaluation of Urolithin A’s potential to resynchronize circadian rhythms and mitigate age-related sleep disturbances.

Key Study Design Features:

Inclusion Criteria: Targets subclinical individuals with impaired sleep quality (PSQI score >5) but no pathological diagnosis, excluding those dependent on caffeine/alcohol.

Multidimensional Assessment:

Subjective: Sleep quality scores, chronotype questionnaire, daytime dysfunction scales.

Objective: Continuous actigraphy monitoring, polysomnography (PSG) analysis.

Biomarkers: NAD+ levels, DNA methylation age, inflammatory markers (IL-6, TNF-α), cortisol rhythm, circadian proteins (BMAL1, PER2), insulin resistance (HOMA-IR), immunoglobulin levels.

“We aim to uncover the causal link between sleep disorders and ageing using epigenetic clocks and metabolic markers, beyond just tracking sleep duration,” stated Professor Chen, the lead investigator. “Combining Urolithin A, a circadian regulator, with the senolytic Fisetin explores synergy for novel solutions, like menopausal sleep issues.”

Scientific Commitment: Building a Health Ecosystem

As a leading high-quality ingredient producer, Bonerge’s R&D follows a pipeline of ‘ingredient science, mechanistic research, clinical translation’. The company is actively seeking global clinical partners from academia and industry to explore Urolithin A’s potential in sleep health and cellular ageing intervention.

Amidst the anti-ageing industry’s shift from consumerism to scientific rigor, Bonerge positions Urolithin A not just as a standalone ingredient, but as a catalyst for evidence-based solutions. Focused on core mechanisms like cellular senescence, Bonerge develops innovative ingredients targeting cellular health, forming a robust “health ecosystem.” Key components include:

Fisetin: Potent senolytic selectively clearing senescent cells and reducing their formation, retarding aging in skin, ovarian, and neural tissues.

Urolithin A: Regulates circadian rhythms, boosts endogenous NAD+ synthesis, enhances cellular repair, and improves sleep quality and reproductive health.

L-Ergothioneine: Unique antioxidant with a dedicated transporter (OCTN1), accumulating in high-stress tissues to neutralize ROS, protecting DNA and telomeres.

PQQ Disodium: Activates the PGC-1α/PPARγ pathway, driving mitochondrial DNA replication and biogenesis.

S–Equol: Natural, non-steroidal estrogenic metabolite with high affinity for ERβ, offering a safer alternative for menopause health.

About Bonerge

Bonerge firmly contends that the future of anti-ageing hinges on evidence-based solutions. These solutions are grounded in well-defined biological mechanisms, supported by robust scientific data, and tailored to precise applications, ultimately delivering comprehensive, science-validated health benefits. For more detailed information about our clinical findings, discover more about us at http://www.bonerge.com.

Contacts

Cecilia Yang

sales@bonerge.com